盈喜预告接连发布：BD成估值新锚，药企加速跨越生死线

Core Insights - The pharmaceutical industry in China is witnessing a significant shift, with companies like Xiansheng Pharmaceutical and Sanofi Health achieving remarkable profit growth, indicating a collective move towards profitability among innovative drug companies in 2025 [1][2][9] Company Performance - Xiansheng Pharmaceutical expects revenue of approximately RMB 77 billion to 78 billion for the fiscal year 2025, representing a year-on-year growth of 16.0% to 17.6%, with net profit projected to reach RMB 13 billion to 14 billion, marking an increase of 80.1% to 93.9% [1] - Sanofi Health reported an estimated revenue of approximately RMB 41.99 billion for 2025, a staggering increase of 251.81%, with net profit expected to rise by 317.09% to around RMB 29.39 billion [1] - The growth for both companies is attributed to increased revenues from innovative drugs, licensing income, and net gains from the fair value of investment portfolios [1] Industry Trends - The year 2025 is marked as a "breakout year" for business development (BD) in China's innovative drug sector, with total BD transactions reaching $135.65 billion, surpassing the U.S. for the first time [3][4] - The number of BD projects increased significantly, with 165 projects reported, and upfront payments exceeding $7.03 billion, reflecting a year-on-year growth of over 226.8% [3][4] - The trend indicates a shift from being a technology-importing country to a technology-exporting one, highlighting China's evolving role in the global pharmaceutical landscape [3] Financial Models - BD transactions are becoming a predictable and sustainable source of income for companies, transforming their financial structures from high-risk, high-investment models to those with multi-stage returns [5][6] - Companies like Heng Rui Pharmaceutical are seeing substantial growth in overseas licensing deals, with overseas revenue reaching RMB 1.93 billion, a 45.2% increase [5] Market Dynamics - There is a stark contrast in performance among companies, with leading firms like Xiansheng Pharmaceutical and Sanofi Health experiencing profit surges, while others like Baili Tianheng face significant revenue declines due to high R&D costs and reduced licensing income [7][8] - The industry is witnessing a clear divide, where companies with strong BD capabilities and innovative pipelines thrive, while those reliant on traditional models struggle [7][8] Future Outlook - The innovative drug sector is expected to continue its upward trajectory into 2026, with ongoing BD transactions indicating a robust market environment [4][9] - Investors are advised to evaluate companies not only on their R&D pipeline density but also on the global recognition of their products, as evidenced by the substantial profit increases seen in leading firms [9]